TIDMEKF
EKF Diagnostics Holdings PLC
09 June 2022
RNS Reach
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Launch of EKF Link
Digital connectivity solution driven by client demand
Enabling hospitals, labs and GPs to manage and evaluate patient
data easily and securely
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global
diagnostics business , announces the launch of EKF Link, a digital
connectivity solution for the secure management of point-of-care
("POC") analysers and associated data on one centralised platform.
The EKF Link middleware links to EKF's own product portfolio and
can also provide connectivity to selected third-party POC
analysers, to enable real-time remote management of data, such as
patient test results, quality control ("QC") /calibration results,
operator management and analyser configuration.
EKF Link is a downloadable software package that allows POC
analysers to connect to a hospital or laboratory's IT system,
enabling data transfer from these remote analysers for subsequent
processing, thereby enhancing their capabilities. This provides
hospitals, laboratories and clinicians with the connectivity and
functionality to manage and evaluate their patient and operator
data, easily and securely. It also allows the remote operators to
capture patient information, perform a QC test, lock-out
unauthorised users and transfer information directly into the
laboratory information management system.
EKF's portfolio of POC diagnostic devices includes its range of
Hematology analysers: Hemo Control and DiaSpect Tm hemoglobin, as
well as its Diabetes range of analysers: Quo-Lab and Quo-Test
HbA1c. All of these can now be digitally connected from anywhere
and securely accessed remotely at any time using EKF Link, compared
to current methods whereby data generated from POC analysers are
either kept as written records, printed out, or in some cases
connected via Bluetooth or data cable.
The development and launch of EKF Link has been driven by
customer demand and designed in partnership with hospital POC
managers to ensure the software meets their specific needs. EKF
Link provides the Company with improved competitive positioning for
future POC contract tenders and new accounts, and increases the
attractiveness of the EKF product portfolio to existing customers
against currently available technologies.
For more information visit:
https://www.ekfdiagnostics.com/ekf-link.html
Mike Salter, CEO, of EKF Diagnostics said: "As part of our
strategy to enhance our POC analyser portfolio and technology
offering, we are pleased to announce that we have successfully
launched EKF Link enabling practitioners to analyse their patients'
results remotely, easily and securely. EKF Link provides our POC
diagnostic devices with a connectivity advantage which positions us
well for tenders and new accounts. This is particularly true in
Europe and North America, where a connectivity solution is commonly
a part of the specification. EKF Link has the added benefit that it
can be installed wherever it is needed, on a PC or a central
server, allowing hospitals and laboratories, technicians and
clinicians to access results from various settings, reducing
workload whilst increasing the security of handling patient
data.
"This new product launch shows our responsiveness to our
customer base and increasing demand for data management
capabilities. It extends the utility of our installed instrument
base and provides EKF with a key advantage for further new business
opportunities."
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Mike Salter, CEO Tel: +44 (0)29 2071 0570
Marc Davies, CFO
Singer Capital Markets (Nominated Adviser & Tel: +44 (0)20 7496 3000
Joint Broker)
Aubrey Powell / George Tzimas
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams / Ben
Farrow
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading global diagnostics business with custom
manufacturing facilities across sites in the US, UK and Europe for
a variety of life science products. EKF is focussed on the
following areas:
Point-of-Care Providing a portfolio of Point-of-Care analysers and
consumables, particularly for use in the area of Hematology
and Diabetes, for use in hospital and research laboratories,
doctor's offices, blood banks and for in-field anaemia
screening programmes. EKF has an estimated 80,000
hemoglobin, hematocrit, HbA1c, glucose and lactate
analysers in regular use across more than 100 countries.
Central Laboratory Clinical chemistry, Small lab analysers, Centrifuges
Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycates
Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
Life Sciences Enzyme fermentation, Custom products and Bulk fermentation
Contract Manufacturing Bulk formulation, Sample collection kits, Private
labelling, Molecular and forensic kits
Laboratory Services In September 2021, EKF completed the acquisition of
Advanced Diagnostic Laboratory LLC ("ADL Health"),
a Texas based testing laboratory certified under the
Clinical Laboratory Improvement Amendments ("CLIA")
for high complexity testing. The laboratory provides
testing for a variety of clinical, forensic and microbiological
sample types using a range of analytical techniques.
This acquisition positions EKF as a leading 'one stop'
provider of diagnostic products and services from
sample collection to results.
EKF's growth strategy to 2024 and beyond can be summarised
as:
-- continuing innovation in products and services in Point-of-Care,
Central Laboratory and Life Sciences leveraging new and existing
routes to market and relationships;
-- investment in expanded production and kitting capabilities to offer
a suite of diagnostic Contract Manufacturing solutions to third
party businesses;
-- expansion of CLIA Laboratories Testing offering, building on the
acquired capabilities in ADL Health; and
-- identify complementary earnings-enhancing acquisitions with key
strategic value.
EKF will also continue to generate enhanced shareholder value
through:
-- a progressive dividend policy; and
-- its agreement with Mount Sinai Innovation Partners ("MSIP"), which
allows us advanced access to innovative commercial opportunities
and where we can build on the ongoing successes of Renalytix plc,
Verici Dx plc and Trellus Health plc.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUAUQUPPGMR
(END) Dow Jones Newswires
June 09, 2022 02:03 ET (06:03 GMT)
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
